Publish in this journal
Journal Information
Vol. 218. Issue 5.
Pages 244-252 (June - July 2018)
Share
Share
Download PDF
More article options
ePub
Visits
...
Vol. 218. Issue 5.
Pages 244-252 (June - July 2018)
Review
DOI: 10.1016/j.rceng.2018.01.004
Treatment and prevention of invasive pneumococcal disease
Tratamiento y prevención de la enfermedad neumocócica invasiva
Visits
...
A.R. Domínguez-Alegríaa,
Corresponding author
alegria.rda@gmail.com

Corresponding author.
, V. Pintadob, I. Barbollaa
a Servicio de Medicina Interna, Hospital Ramón y Cajal, Madrid, Spain
b Servicio de Enfermedades Infecciosas, Hospital Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Tables (4)
Table 1. Resistance of pneumococcus to the main antimicrobials.
Table 2. Risk factors for infection by antibiotic-resistant S. pneumoniae.
Table 3. Influence of combined antibiotic therapy on mortality in pneumococcal infections.
Table 4. Indications for pneumococcal vaccination in adults.
Show moreShow less
Abstract

Invasive pneumococcal disease is a severe infection that mainly affects patients with associated comorbidity. The pediatric conjugate vaccination has resulted in a change in the adult vaccination strategy. The antibiotic resistance of pneumococcus is not currently a severe problem. Nevertheless, the World Health Organisation has included pneumococcus among the bacteria whose treatment requires the introduction of new drugs, such as ceftaroline and ceftobiprole. Although the scientific evidence is still limited, the combination of beta-lactams and macrolides is recommended as empiric therapy for bacteraemic pneumococcal pneumonia.

Keywords:
Streptococcus pneumoniae
Invasive pneumococcal disease
Resistance
Combined therapy
Vaccine
Resumen

La enfermedad neumocócica invasiva es una infección grave que afecta principalmente a pacientes con comorbilidad asociada. El beneficio de la vacuna conjugada infantil ha condicionado un cambio de la estrategia de vacunación en el adulto. La resistencia a antibióticos no supone un problema grave en la actualidad, a pesar de lo cual la Organización Mundial de la Salud ha incluido al neumococo entre las bacterias cuyo tratamiento requiere la introducción de nuevos fármacos, como ceftarolina y ceftobiprol. Aunque la evidencia científica es todavía limitada, se recomienda la asociación de betalactámicos y macrólidos como terapia empírica de la neumonía neumocócica bacteriémica.

Palabras clave:
Streptococcus pneumoniae
Enfermedad neumocócica invasiva
Resistencia
Terapia combinada
Vacuna

Article

These are the options to access the full texts of the publication Revista Clínica Española (English Edition)
Member
Si es usted socio de FESEMI siga los siguientes pasos:

Diríjase desde aquí a la web de la >>>FESEMI<<< e inicie sesión mediante el formulario que se encuentra en la barra superior, pulsando sobre el candado.

Una vez autentificado, en la misma web de FESEMI, en el menú superior, elija la opción deseada.

>>>FESEMI<<<

Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Revista Clínica Española (English Edition)

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
Email
Idiomas
Revista Clínica Española (English Edition)

Subscribe to our newsletter

Article options
Tools
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?